STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo (STO:ORX) has strengthened its clinical and regulatory team with the appointment of three senior executives - Mats Eriksson PhD, VP Research and Clinical Development and Medical Director for Orexo, Christina Ståhl MSc. Pharm, Vice President Regulatory Affairs, and Anne Marie Ciupitu MSc, PhD, Director QA/QC.
